Momentum In Women’s Health, But Big Obstacles Too

Unmet Need In Space Was A Theme At J.P. Morgan

Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.

(Shutterstock)
Key Takeaways
  • Women’s health was a theme at the J.P. Morgan Healthcare Conference, which held a series of panel discussions on the topic.
  • Investment in women’s health continues to lag despite a big opportunity and unmet need.
  • Panelists said early investment from venture investors is hard to obtain, stifling innovation.

Women’s health remains a big area of unmet medical need and since women make up half the population, the commercial opportunity is enormous, but investment in therapeutics for women – whether for female-specific conditions like

The topic of women’s health was a theme at the J.P

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Women's Health

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By 

Adstiladrin sales hit €70m in first full year on the market

Cosette Bolsters Women’s Health, Dermatology Portfolios With Mayne Buyout

 
• By 

Deal Snapshot: Cosette will acquire struggling Mayne Pharma for about $430m, thereby augmenting its women’s health and dermatology portfolio and enhancing commercial capabilities.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

 

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.

Momentum In Women’s Health, But Big Obstacles Too

 

Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.

More from Conferences